All News
Rheumatology Roundup - ACR 2023
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
Read Article
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
Dr. John Cush RheumNow ( View Tweet)
Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23
Feasible after early remission induction https://t.co/WwiNp8WKDC
Dr Gurdeep S Dulay ( View Tweet)
Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer
.Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
Rohit Aggarwal ( View Tweet)
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
Robert B Chao, MD ( View Tweet)
Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
Dr. Antoni Chan ( View Tweet)
Continued interest on CAR-T cells in systemic sclerosis!
6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall
Skin findings improved in all 3 pts
Previous finger ulcerations resolved
Lung function stable in 2 pts, improved in 1
@RheumNow #ACR23 Abs#2598
Robert B Chao, MD ( View Tweet)
#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
Dr. Rachel Tate ( View Tweet)
Interesting late breaker!
Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression
No difference in safety profile compared to placebo
@RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
Robert B Chao, MD ( View Tweet)
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
Md Yuzaiful Md Yusof ( View Tweet)
Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0
Richard Conway ( View Tweet)
L20 @ #ACR23
New therapy on the horizon for RA pts that failed MTX?
⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL
➡️ placebo-controlled, phase III trial, 24w
👉at wk 24, PBO pts switched to drug arm for 24 more wks
➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/XvNMXAFkWe https://t.co/HVvBLhqe8H
Dr. John Cush RheumNow ( View Tweet)
👨⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23
By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ
Mithu Maheswaranathan, MD ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)
ARTIC REWIND RCT 3 yrs csDMARD withdrawal
38% 3yrs csDMARDs free remission vs. 80% stable dose gpe
75% recovery after restart
Rx progression 19% in half dose gpe
More use bioDMARDs (18%) & GCs (50%) withdraw gpe
Trends towards lower infections
@RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS
Aurelie Najm ( View Tweet)
#CAR T cells #ACR23
🔥Back to back Sessions on one of the most avidly researched area in Rheum!
💡Check out these slides to understand:
☣️Toxicities and Limitations of CAR T therapy
🆕 Novel CAR designs
⚡️CAR cell sources
❓Research Questions to ponder!
#ACRambassador https://t.co/6sOn4rjqY3
debaditya_roy ( View Tweet)
Toxicities and limitations of CAR therapy:
the other side of its incredibly exciting, boundless potential
@Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC
David Liew drdavidliew ( View Tweet)
Dr. Sadelain gives a tour-de-force CAR-T overview for the future. Questions around programming antigen sensitivity and the life span of therapy are just the tip of the iceberg. #ACR23 @RheumNow https://t.co/oLog0SiQoE
Dr. Rachel Tate ( View Tweet)
